Intravenous Use of Prescription Psychostimulants; A Comparison of the Pattern and Subjective Experience between Different Methylphenidate Preparations, Amphetamine and Cocaine
| Autor: | Bjarni O. Rafnar, Andres Magnusson, Gudrun Dora Bjarnadottir, Magnus Johannsson, Engilbert Sigurdsson, Steinn Steingrimsson, Helena Bragadottir, H. Magnus Haraldsson |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Health (social science) Subjective effects Drug Compounding Iceland Medicine (miscellaneous) Injection rate Euphoriant 03 medical and health sciences Intravenous use Young Adult 0302 clinical medicine Cocaine mental disorders medicine Humans 030212 general & internal medicine Medical prescription Psychiatry Amphetamine Prescription Drug Misuse Treatment seeking Methylphenidate Euphoria Psychiatry and Mental health Cross-Sectional Studies Delayed-Action Preparations Administration Intravenous Central Nervous System Stimulants Female Psychology human activities 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | European addiction research. 22(5) |
| ISSN: | 1421-9891 |
| Popis: | Background/Aims: Methylphenidate (MPH) has been the most commonly used intravenous (i.v.) substance in Iceland in recent years. In Iceland, MPH is available in 3 forms: immediate-release (IR) tablets (MPH IR, short-acting), sustainable-release (SR) capsules (MPH SR, long-acting) and osmotic-release (OROS) tablets (MPH OROS, long-acting). The aims of the study were to compare the pattern and subjective effects of i.v. MPH use to other i.v. psychostimulants and examine whether the pattern of use differs among MPH preparations. Methods: This is a nationwide descriptive study. Information was collected from 95 i.v. substance users undergoing inpatient detoxification and reporting i.v. MPH use in the last 30 days using a semi-structured interview. Results: MPH SR was both the most commonly used (96%) and preferred i.v. psychostimulant (57%). The intensity and duration of ‘euphoria' did not differ between cocaine and MPH SR. No participant reported MPH OROS as their preferred substance even though a third had used it in the past month. Conclusions: The pattern of i.v. MPH use is similar to other psychostimulants among treatment seeking patients. MPH OROS was the least preferred i.v. psychostimulant, despite having the largest market share in Iceland. The results indicate that MPH OROS has less abuse potential than other MPH preparations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|